Editorial Board Members’ Collection Series: Advance in Breast Cancer

Dear Colleagues, 

Breast cancer (BC) is the most common cancer in women and the second leading cause of female cancer deaths, remaining a major medical and socioeconomic burden. Adjuvant chemotherapy has been the standard of care for early BC patients; however, in the 2000s, it was realized that most of these patients, especially those who are in early-stage disease, hormone-receptor-positive, and lymph-node-negative, are being over-treated, and clinical and histological features may not be enough to make decisions regarding adjuvant therapy. These patients are at risk of being undertreated or overtreated with endocrine therapy and chemotherapy, and these tests have the potential to save an important number of patients for whom chemotherapy may have potentially harmful side effects. Thus, the role of molecular data has become increasingly important in guiding therapeutic decisions in this setting. In recent years, molecular tests which have been recommended in clinical guidelines have become commercially available. However, it is known that genomics tests have an important cost and not all centers are provided with laboratories performing this type of analyses. In this context, the emerging and promising spread of radiomics analysis in symbiosis with the evolution of artificial intelligence techniques for the assessment of biomedical data represents a huge asset that can be spent for the development of systems supporting therapeutic decisions.

In addition, current imaging modalities for diagnosis and staging of breast cancer comprise mammography, digital breast tomosynthesis, ultrasound, contrast-enhanced mammography, magnetic resonance imaging (MRI), nuclear medicine imaging, as well as hybrid techniques such as PET/CT and PET/MRI. Radiomics/-genomics image analysis and artificial intelligence may aid in better differentiating between benign and malignant entities, and patient characteristics, to better stratify patients according to several factors.

In this Special Issue titled “Advance in Breast Cancer”, authors focusing on current and future challenges in breast cancer imaging, ranging from diagnosis to prognosis and response to systemic treatments, are welcome to submit papers exploring these topics.

Dr. Alessandro Rizzo
Dr. Daniele La Forgia
Dr. Gianluca Gatta
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• breast cancer
• mammography
• artificial intelligence
• ultrasound
• digital pathology
• contrast-enhanced mammography
• digital breast tomosynthesis
• radiomics
• radiogenomics